21 min listen
Adapting Biopharma to AI with Greg Meyers
FromRaising Health
ratings:
Length:
34 minutes
Released:
Apr 2, 2024
Format:
Podcast episode
Description
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Released:
Apr 2, 2024
Format:
Podcast episode
Titles in the series (100)
Journal Club: Turning a Toxin into a Genome Editing Tool: In this episode of Journal Club we discuss the development of the first genome editing enzyme capable of performing precision edits to the mitochondrial genome. Mutations in the mitochondrial genome cause over 150 different human diseases, but none of our existing gene editing tools have been able to edit this DNA. This newly developed tool can be used to create better models of these diseases and and perhaps one day be used to treat them with gene therapy. by Raising Health